Summary

Overview
Global aerosol delivery device market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Aerosol is a suspension system of solid or liquid particles in a gas, typically air. It allows for medication to be delivered directly to the bloodstream through the lungs, without the complications of an IV, such as pain and injection site infection. This technique is primarily used for dosing medication for lung conditions, including asthma, but it may be beneficial for other therapies as well.
Market Dynamics: Drivers & Restraints
Growing Prevalence of Respiratory Diseases
The growing prevalence of respiratory diseases is expected to boost the global market growth during the forecast period. For instance, according to the World Health Organization (WHO) 2021 factsheet, COPD was among the third-leading reason of death globally, inducing 3.23 million casualties in 2020. More than 80% of these casualties happened in low and middle-income countries (LMIC).
Also, according to the Asthma and Allergy Foundation of America in March 2021, approximately 1 in 13 Americans had asthma, which was approximately 25 million individuals. Asthma is among the biggest contributors to this formation, involving children, adults, and geriatric individuals. The same reference remarked that almost 5 million American children had asthma.
Furthermore, the technological advancements, rise in research activities, increaseing investments and growing awareness are among the other additional factors boosting the global market growth during the forecast period.
Product Recalls
The increasing incidences of product recalls from market are expected to hamper the global market growth during the forecast period. for instance, Cipla Limited's wholly-owned associate, Cipla USA Inc., willingly recalled six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level with the knowledge of the U.S. Food and Drug Administration. Furthermore, stringent regulatory bodies, and high development costs are other additional factors hampering the global market growth during the forecast period.
Segment Analysis
The global aerosol delivery device market is segmented based on product, application, distribution channel and region.
Metered Dose Inhalers are Expected to Dominate Market
Owing to the increasing authorizations from the regulatory bodies for metered dose inhalers, the segment is expected to dominate the global market during the forecast period. For instance, in October 2021, BreatheSuite obtained 510(k) authorization from the FDA for its Metered-Dose Inhaler V1 device, which turns existing inhalers into smart inhalers for individuals with asthma and COPD. Moreover, in July 2023, Lupin's subsidiary unit Hormosan Pharma GmbH introduced a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increasing approvals in North America the region is expected to dominate the global market during the forecast period. For instance, in July 2023, Viatris Inc., a multinational healthcare corporation, and Kindeva Drug Delivery introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the foremost generic version of AstraZeneca's Symbicort with an Abbreviated New Drug Application (ANDA) authorized by the U.S. Food and Drug Administration (FDA). Moreover, in February 2020, The US Food and Drug Administration (FDA) authorized the foremost generic of ProAir HFA (albuterol sulfate) inhalation aerosol to treat or prevent bronchospasm in individuals of four years of age and older with reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients four years of age and older.
COVID-19 Impact Analysis
As SARS-CoV-2 directly targets the lungs and initiates lung damage, treating COVID-19 with inhalants presents multiple benefits over the enteral/parenteral administration. Inhaled drug delivery delivers higher drug concentrations, particularly in the pulmonary system. This allows the lessening of systemic side effects and delivers a quick clinical reaction, therefore, the pandemic has led to an increase in the demand for and investments in aerosol delivery devices, positively impacting the global market during the pandemic.
Market Segmentation
By Product
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
By Applications
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Non-Respiratory Diseases
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2022, United Therapeutics Corporation obtained FDA authorization for its Tyvaso DPI, an inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases.
• In January 2023, AstraZeneca obtained authorization from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra strives to decrease the threat of asthma exacerbations in people aged 18 years and older.
Competitive Landscape
The major global players in the market include 3M Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc. and MannKind Corporation among others.
Why Purchase the Report?
• To visualize the global aerosol delivery device market segmentation based on product, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aerosol delivery device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global aerosol delivery device market report would provide approximately 62 tables, 58 figures and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence of Respiratory Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Product Recalls
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Product Trend
5.6. Unmet Need
5.7. Epidemiology Analysis
5.8. SWOT Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Dry Powder Inhalers*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Metered Dose Inhalers
7.4. Nebulizers
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Asthma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chronic Obstructive Pulmonary Disease (COPD)
8.4. Cystic Fibrosis
8.5. Non-Respiratory Diseases
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. 3M Company, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline plc
12.3. Teva Pharmaceutical Industries Ltd., Inc.
12.4. Cipla Inc.
12.5. Boehringer Ingelheim International GmbH
12.6. AstraZeneca,
12.7. Pfizer Inc
12.8. Merck & Co., Inc.
12.9. Genentech USA, Inc.
12.10. MannKind Corporation
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us